Profil bibliographique

Vinie Kouamou

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

48Publications signalées

339Citations signalées

4Affiliations récentes

Institutions déclarées

University of Zimbabwe Office of Extramural Research Department of Research and Specialist Services Infectious Diseases and the Research Institute

Domaines associés

HIV/AIDS drug development and treatmentHIV/AIDS Research and InterventionsHIV Research and TreatmentHIV-related health complications and treatmentsHIV/AIDS Impact and Responses

Publications récentes

Accès ouvert 2026 preprintOpenAlex

Circulating plasma microRNA expression profiles associated with virological failure and HIV drug resistance among adults receiving second-line protease inhibitor-based antiretroviral therapy in Zimbabwe

Justin Mayini, Tendai Washaya, Justen Manasa, Edward Zumbika et autres

0 citationsResearch Square

Accès ouvert 2026 articleOpenAlex

Major protease inhibitor drug resistance mutations among patients with virological failure on second-line antiretroviral therapy in Zimbabwe: a retrospective cross-sectional study

Justin Mayini, Tendai Washaya, Justen Manasa, Edward Zumbika et autres

0 citationsVirology Journal

Accès ouvert 2026 articleOpenAlex

Predictors of smart pillboxes adoption intent among people living with HIV in Cameroon: a cross-sectional study

Armel F. Setubi, Bryan Shaw, Katherine Robsky, Ignace Gashongore et autres

0 citationsBulletin of the National Research Centre/Bulletin of the National Research Center

Accès ouvert 2026 articleOpenAlex

Efficacy and safety of short-cycle, dolutegravir-based antiretroviral therapy in adolescents living with HIV (BREATHER Plus): a multicentre, open-label, randomised, parallel, two-arm, non-inferiority trial

Adeodata Kekitiinwa, Angus Jennings, Mutsa Bwakura-Dangarembizi, Cissy Kityo et autres

0 citationsThe Lancet HIV

Accès ouvert 2026 articleOpenAlex

Trial design and enrolment characteristics of LATA (Long-Acting Treatment in Adolescents): A randomised, open-label, non-inferiority, 96-week trial evaluating the virological efficacy, safety, acceptability and quality-of-life of the dual long-acting injectable regimen cabotegravir/ rilpivirine compared to daily oral therapy in virologically suppressed adolescents with HIV-1 infection, aged 12 to <20 years, in Sub-Saharan Africa

Diana Anena, Elizabeth Chappell, Rashidah Nazzinda, Cecilia Kiilu et autres

1 citationContemporary Clinical Trials

Accès ouvert 2025 articleOpenAlex